Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ImmunityBio, Inc.
University of Pittsburgh
Mayo Clinic
University of Pittsburgh
7 Hills Pharma, LLC
Incyte Corporation
University of Pittsburgh
Children's National Research Institute
Molecular Templates, Inc.
Fate Therapeutics
Jules Bordet Institute
Incyte Corporation